Navigation Links
Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
Date:10/10/2010

MILAN, ITALY - October 10, 2010 - Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously reported outcomes for patients receiving chemotherapy alone. Dr. Miklos Pless, head of medical oncology at the Winterthur Hospital Cancer center in Switzerland, presented the data at the European Society for Medical Oncology Congress (ESMO).

Physicians delivered TTF Therapy to patients in the study using the NovoTTF-100La portable, non-invasive medical device. Investigators conducted this single arm, phase II study at four centers in Switzerland, enrolling 42 patients with locally advanced and metastatic NSCLC (stage IIIb-IV) who had failed prior treatments with chemotherapy. Patients in the study received TTF Therapy for 12 hours a day in combination with pemetrexed (Alimta; Eli Lilly) until disease progression.

Advanced NSCLC is the second cancer in which TTF Therapy has shown clinical efficacy in human trials. Novocure reported a successful phase III clinical trial of TTF monotherapy in patients with recurrent glioblastoma, an aggressive form of brain cancer, at the American Society for Clinical Oncology Conference (ASCO) earlier this year. Results of this phase III trial have been filed with the U.S. Food and Drug Administration (FDA).

"We were pleased to report on the results of this multi-center trial of TTF Therapy in a non-brain tumor indication," said Dr. Pless. "We believe this study has shown TTF Therapy to be completely non-toxic and to have the potential to act as a significant adjunct to chemotherapy in the treatment of NSCLC and other solid tumor indications."

Patients treated with TTF Therapy in combination with pemetrexed had a median overall survival time of 13.8 months compared with the 8.3 months reported for pemetrexed alone. The one-year survival rate for
'/>"/>

Contact: Anne McPherson
anne.mcpherson@edelman.com
415-486-3273
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related biology news :

1. Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
2. GEN reports on the greening of the life sciences
3. Aware, Inc. Reports Second Quarter 2010 Financial Results
4. GEN reports on rediscovered technology to bolster proteomics research
5. BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results
6. International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit
7. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
8. New climate change reports underscore need for action
9. BIO-key(R) Reports First Quarter 2010 Financial Results
10. Survey reports latest honey bee losses
11. Grupo Radio Centro Reports First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
(Date:6/23/2015)... RALEIGH, N.C. , June 23, 2015 /PRNewswire/ ... technology, today announced the results of a recent ... unmatched accuracy on the wrist during activity. In ... biometric technology was compared along with the Apple ... for accurately measuring heart rate during activity. The ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... ) can today be found all over Central Europe, Asia, ... in the Iberian Peninsula at the end of the Early ... an international research study, with Spanish participation, which has discovered ... of fossils found in the Cueva Victoria deposit in Cartagena ...
... of newly installed, hands-free faucets at The Johns Hopkins Hospital, ... hands and dispense preset amounts of water, shows they were ... common and hazardous bacteria in hospitals compared to old-style fixtures ... "Newer is not necessarily better when it comes to ...
... (SACRAMENTO, Calif.) UC Davis cancer researchers have found ... for surveillance with regular CT scans over lymph node ... findings, published online last week in the journal Cancer, ... cancers with surveillance when discussing treatment options with their ...
Cached Biology News:Green toad inhabited Iberian Peninsula 1 million years ago 2Latest hands-free electronic water faucets found to be hindrance, not help, in infection control 2Latest hands-free electronic water faucets found to be hindrance, not help, in infection control 3Latest hands-free electronic water faucets found to be hindrance, not help, in infection control 4Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 3
(Date:7/3/2015)... -- Pomerantz LLP announces that a class action lawsuit has ... "Company")(NYSE: PBYI ) and certain of its officers.   ... Central District of California , and ... consisting of all persons or entities who purchased Puma ... inclusive (the "Class Period").  This class action seeks to ...
(Date:7/2/2015)... ELLYN, Ill. , July 2, 2015 ... Colton Eakins are gaining invaluable real-world experiences ... of Technology this summer. The students will ... Dr. Jeff Wereszczynski,s research group at IIT. The ... Dr. Tom Carter , Physics; Dr. Kathy ...
(Date:7/2/2015)... ... July 02, 2015 , ... Sleepless nights will become obsolete ... of sleep, launched its Indiegogo campaign on June 23. Sound sleepers and the sleep ... makes it effortless to use, while the integration of the Bluetooth speaker, alarm clock ...
(Date:7/1/2015)... and PARIS , July ... and Genective, key developer of biotech crops, today ... of new generations of insect control traits. ... to counter the realities of advancing insect resistance. ... AgBiome,s unique insect control technology with Genective,s capability ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4COD Students Participate in Prestigious Summer Internships 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3AgBiome and Genective collaborate to create novel insect-resistant crops 2
... December 11 Olympus has further,cemented its position as ... signing an exclusive and immediate deal to distribute the ... the sole global,provider of ports for state-of-the-art laparoscopic operative ... Olympus is now the exclusive,distributor for the full range ...
... PPHM ) today announced that Thomas A. Waltz, M.D., ... Dr. Waltz had been a director of Peregrine since 2004 ... death, Dr. Waltz served on Peregrine,s Audit Committee, Compensation Committee and ... "The sudden loss of our business colleague and friend Tom Waltz ...
... Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) ... statistical endpoint in its multi-centre Phase 2 clinical ... in patients with various sarcomas that have metastasized ... of patients on study with significant, durable, clinically ...
Cached Biology Technology:Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts 2Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz 2Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 2Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 3Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 4
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
... BMH 71-18 mutS and ES1301 mutS ... coli. Use of these strains prevents repair ... leading to high mutation efficiencies and making ... GeneEditor and Altered Sites II Mutagenesis Systems. ...
propidium iodide *1.0 mg/mL solution in water*...
Biology Products: